Market: KLS |
Currency: USD
Address: 5 Park Plaza
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
📈 AEON Biopharma, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$1.54
-
Upside/Downside from Analyst Target:
38.74%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.013889 |
- |
2025-02-26 |
- |
Stock split |
|
Total Amount for 2025: $0.013889 |
📅 Earnings & EPS History for AEON Biopharma, Inc.
| Date | Reported EPS |
|---|
| 2025-08-12 | -0.6 |
| 2024-11-13 | -11.52 |
| 2024-08-12 | 5.34 |
| 2024-05-14 | -104.8 |
| 2024-03-29 | -51.12 |
| 2023-11-13 | 82.8 |
📰 Related News & Research
No related articles found for "aeon biopharma".
